Mineralys Therapeutics, Inc. MLYS Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedEmployeeBenefitsCurrent.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s accrued compensation?
- Mineralys Therapeutics, Inc. (MLYS) reported accrued compensation of $2.31M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s accrued compensation changed year-over-year?
- Mineralys Therapeutics, Inc.'s accrued compensation increased by 101.0% year-over-year, from $1.15M to $2.31M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s accrued compensation?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s accrued compensation has grown at a 102.7% compound annual growth rate (CAGR), from $665K to $5.54M.
- What does accrued compensation mean?
- Employee wages, salaries, bonuses, commissions, and benefits earned but not yet paid as of the reporting date.